SCHEMBL30101340

SCHEMBL30101340

c1cc2c(c(OCCN3CCCCC3)c1)CNC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.69
TSHR P16473 1/20 0.54
TDP1 Q9NUW8 1/20 0.51
POLB P06746 1/20 0.50
HRH1 P35367 3/20 0.49
DRD1 P21728 2/20 0.49
DRD4 P21917 2/20 0.49
DRD5 P21918 2/20 0.49
DRD3 P35462 2/20 0.49
DRD2 P14416 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48
HSD17B10 Q99714 1/20 0.48
BACE1 P56817 1/20 0.47
TRPM2 O94759 1/20 0.46
PARP1 P09874 1/20 0.46
TIPARP Q7Z3E1 1/20 0.46
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30101386 0.89 HRH3 (0.55) HRH3TDP1POLBTIPARPKDM4E
SCHEMBL30101435 0.89 HRH3 (0.58) HRH3TSHRTDP1POLBTIPARP
SCHEMBL30101416 0.86 HRH3 (0.53) HRH3TSHRPOLBDRD1DRD4
SCHEMBL6658901 0.82 HRH3 (1.00) HRH3HRH1CYP2D6CYP2C19TRPM2
SCHEMBL14287592 0.82 HRH3 (0.82) HRH3HRH1CYP2D6CYP2C19TRPM2
SCHEMBL30101529 0.81 TIPARP (0.55) HRH3DRD3DRD2TIPARPKDM4E
Hydrochloric Acid SCHEMBL5106963 0.81 HRH3 (0.98) HRH3HRH1CYP2D6CYP2C19TRPM2
Hydrochloric Acid SCHEMBL5107481 0.81 HRH3 (0.80) HRH3HRH1CYP2D6CYP2C19TRPM2
SCHEMBL467681 0.81 HRH3 (0.76) HRH3TDP1CYP1A2CYP2D6CYP2C19
SCHEMBL383947 0.80 HRH3 (0.61) HRH3TSHRCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HRH3 1405/4885TSHR 3587/4885TDP1 223/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 HRH3 1405/4885TSHR 3587/4885TDP1 223/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 HRH3 1405/4885TSHR 3587/4885TDP1 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.